Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of semaglutide and dulaglutide, both added to metformin, in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,201 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-01 · est. completion 2017-05

Where 209 sites · Bulgaria, Croatia, Finland, Germany, Greece, Hong Kong, India, Ireland, Latvia, Lithuania, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02648204 ↗

Description as written by the study sponsor.

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

Administered subcutaneously (s.c., under the skin) once-weekly.
Dulaglutide Drug

Administered subcutaneously (s.c., under the skin) once-weekly.

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02648204 ↗